Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”
Stay updated with Hemostasis Today.
-
Apr 4, 2026, 08:27Daniel Pereira Monteiro: HbF Raised with HbC and HbA – What to Do Next?
-
Apr 4, 2026, 08:13Eoin McGrath: Common Language for Blood Transfer Across Organizations
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion